Not exact matches
This new study suggests that iPSC -
MSC - secreted factors modulate T cell responses by inhibiting the cleavage of caspases, in what represents a novel
immunomodulatory mechanism [3].
New research demonstrates how proinflammatory stimuli can promote the production of extracellular vesicles from
MSCs with enhanced
immunomodulatory capacity.
The new
immunomodulatory mechanism uncovered employing an in vivo mouse model suggests that iPSC -
MSCs secreted
immunomodulatory factors inhibit the cleavage of caspases and suppress T cell responses to promote an anti-inflammatory environment.
The robust
immunomodulatory capabilities of mesenchymal stem cells (
MSCs) have propelled them into animal studies and preliminary clinical trials as a treatment for a series of immunological diseases.
Researchers studying the effects of iPSC -
MSCs treatment in an in vivo mouse model discover a novel
immunomodulatory mechanism involving caspase proteins
Bartholomew et al 53 first described the in vivo
immunomodulatory properties of
MSCs in a baboon model of skin transplantation.
In addition, the
immunomodulatory effects of
MSCs have been demonstrated in several conditions characterized by inflammation.
BM -
MSCs demonstrate broad therapeutic potential, as seen by their angiogenesis - promoting capacities and their
immunomodulatory properties.
Possible solutions can be provided by use of
MSCs, which are known for their
immunomodulatory properties, iPSCs, which are derived from the patient's own tissue, and of course autologous cell sources.